Monopar Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price
Monopar Therapeutics Inc. (MNPR) had Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price of $45.44 per share as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value
us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue · last filed 2026-08-12
- 2026-06-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $45.44.
- 2026-03-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $45.27.
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $41.57.
- 2025-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price $29.28.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2026-06-30 | $45.44 10-Q · filed 2026-08-12 | |
| 2026-03-31 | $45.27 10-Q · filed 2026-05-14 | |
| 2025-12-31 | $41.57 10-K · filed 2026-03-27 | |
| 2025-09-30 | $29.28 10-Q · filed 2025-11-13 | |
| 2025-06-30 | $27.64 10-Q · filed 2025-08-12 | |
| 2025-03-31 | $27.31 10-Q · filed 2025-05-13 | |
| 2024-12-31 | $10.99 10-K · filed 2025-03-31 | |
| 2024-06-30 | $11.38 10-Q · filed 2024-11-08 | $2.96 10-Q · filed 2024-08-09 |
| 2024-03-31 | $3.30 10-Q · filed 2024-05-09 | |
| 2023-12-31 | $3.37 10-K · filed 2024-03-28 | |
| 2023-09-30 | $3.41 10-Q · filed 2023-11-09 | |
| 2023-06-30 | $3.44 10-Q · filed 2023-08-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B |